LifeHealthcare Group Limited (ASX:LHC) announces its results for the half year ending 31 December 2016.
LifeHealthcare delivered a solid underlying performance for the first half of FY17 with 13.4% revenue growth on the prior comparable period to $61.7 million and underlying EBITDA growth of 7.3% on prior comparable period to $9.1 million.
The key contributors to these results were:
- Above market implant growth with new surgeon growth of 7% in the 1st half;
- Further spinal robotics penetration following the placement of two Mazor Renaissance spinal robotic units bringing the installed base to six;
- High growth in complex lower limb reconstruction including penetration from existing biologics products; and
- The continued growth in interventional cardiology and respiratory, following the acquisition of Medical Vision Australia in October of 2015.
For further information please download PDF attached:
Download this document